Literature DB >> 11584312

Interventional strategies against prion diseases.

A Aguzzi, M Glatzel, F Montrasio, M Prinz, F L Heppner.   

Abstract

Only a few years ago, the idea that transmissible spongiform encephalopathies could be treated pharmacologically would have met with considerable scepticism. Even now, there is no way to cure a patient or animal suffering from a manifest prion disease. But recent, exciting developments seem to indicate that immunological and pharmacological interventions could have some potential for the pre-exposure and post-exposure prophylaxis of prion diseases. Although it is unlikely that we will be able to cure the clinically overt stages of prion diseases in the foreseeable future, palliative and even life-prolonging interventions might no longer be confined to the realm of science fiction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584312     DOI: 10.1038/35094590

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  12 in total

1.  Proteomic consequences of expression and pathological conversion of the prion protein in inducible neuroblastoma N2a cells.

Authors:  Monique Provansal; Stéphane Roche; Manuela Pastore; Danielle Casanova; Maxime Belondrade; Sandrine Alais; Pascal Leblanc; Otto Windl; Sylvain Lehmann
Journal:  Prion       Date:  2010-10-27       Impact factor: 3.931

2.  Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies.

Authors:  Gaetano Donofrio; Frank L Heppner; Magdalini Polymenidou; Christine Musahl; Adriano Aguzzi
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

4.  RNAi: a novel strategy for the treatment of prion diseases.

Authors:  Qingzhong Kong
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

5.  Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection.

Authors:  Magdalini Polymenidou; Frank L Heppner; Erica C Pellicioli; Eduard Urich; Gino Miele; Nathalie Braun; Franziska Wopfner; Hermann M Schätzl; Burkhard Becher; Adriano Aguzzi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

6.  Multiple antigenic peptides facilitate generation of anti-prion antibodies.

Authors:  J Bainbridge; N Jones; B Walker
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

7.  Inhibition of PrP(Sc) formation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives.

Authors:  Fani Koukouli; Ioannis Paspaltsis; Evgenia Salta; Konstantinos Xanthopoulos; Eftychia N Koini; Theodora Calogeropoulou; Theodoros Sklaviadis
Journal:  Prion       Date:  2012-08-23       Impact factor: 3.931

8.  Antiprion prophylaxis by gene transfer of a soluble prion antagonist.

Authors:  Nicolas Genoud; David Ott; Nathalie Braun; Marco Prinz; Petra Schwarz; Ueli Suter; Didier Trono; Adriano Aguzzi
Journal:  Am J Pathol       Date:  2008-03-27       Impact factor: 4.307

9.  The prepared tau exon-specific antibodies revealed distinct profiles of tau in CSF of the patients with Creutzfeldt-Jakob disease.

Authors:  Cao Chen; Qi Shi; Bao-Yun Zhang; Gui-Rong Wang; Wei Zhou; Chen Gao; Chan Tian; Guo-Yong Mei; Yan-Ling Han; Jun Han; Xiao-Ping Dong
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

10.  Biochemical aspects of dementias.

Authors:  Christoph Hock
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.